SCHEMBL22979288

SCHEMBL22979288

CC[C@@H](Nc1nc2ccccc2c2nc(-c3ccc(Cl)cc3OC(F)F)nn12)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.42
MAPT P10636 4/20 0.41
ADORA3 P0DMS8 8/20 0.40
LMNA P02545 2/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
GAA P10253 1/20 0.40
ALPG P10696 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HCRTR1 O43613 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
ADORA2B P29275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646172 1.00 TP53 (0.42) TP53MAPTADORA3LMNAALPL
SCHEMBL22979291 1.00 TP53 (0.42) TP53MAPTADORA3LMNAALPL
SCHEMBL22981120 1.00 TP53 (0.42) TP53MAPTADORA3LMNAALPL
SCHEMBL29645432 1.00 TP53 (0.42) TP53MAPTADORA3LMNAALPL
SCHEMBL29645848 0.90 LMNA (0.40) TP53MAPTADORA3LMNAALPL
SCHEMBL29645710 0.90 LMNA (0.40) TP53MAPTADORA3LMNAALPL
SCHEMBL22979834 0.90 LMNA (0.40) TP53MAPTADORA3LMNAALPL
SCHEMBL22979832 0.90 LMNA (0.40) TP53MAPTADORA3LMNAALPL
SCHEMBL22981252 0.90 LMNA (0.40) TP53MAPTADORA3LMNAALPL
SCHEMBL22981167 0.90 MAPT (0.43) TP53MAPTADORA3LMNAALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US claimed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP claimed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO claimed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 TP53 242/4885MAPT 4047/4885ADORA3 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.